Financial Performance - For the year ended December 31, 2022, the revenue from continuing operations was RMB 2,375.0 million, a decrease of 0.1% compared to RMB 2,377.2 million for the year ended December 31, 2021[57]. - The gross profit from continuing operations for the year ended December 31, 2022, was RMB 927.2 million, down 4.9% from RMB 975.2 million for the year ended December 31, 2021[57]. - The profit attributable to owners of the company for the year ended December 31, 2022, was RMB 290.8 million, compared to RMB 181.6 million for the year ended December 31, 2021[57]. - The company reported a total revenue of HKD 1.2 billion for the fiscal year ending December 31, 2022, representing a year-on-year increase of 15%[72]. - For the year ended December 31, 2022, the adjusted EBITDA for continuing operations was RMB 819.1 million, a decrease of 2.9% compared to RMB 843.2 million for the year ended December 31, 2021[75]. - Total revenue for the year ended December 31, 2022, was RMB 2,375.0 million, slightly down from RMB 2,377.2 million in 2021[77]. - The net profit attributable to the owners of the company for the year ended December 31, 2022, was RMB 290.8 million, compared to RMB 181.6 million in 2021, representing an increase of 60.4%[77]. - Comprehensive hospital business revenue decreased by 10.5% to RMB 609.6 million in 2022, primarily due to an 11.1% decline in inpatient numbers[125]. - Health check-up business revenue increased by 4.1% to RMB 1,765.4 million in 2022, driven by a 0.5% growth in the number of check-ups and a 3.5% increase in average spending per customer[125]. Operational Highlights - The total number of employees increased to 1,500, with a turnover rate of 10% across various demographics[69]. - The number of inpatient visits at Nantong Ruici Hospital reached 26,141 in 2022, down from 29,395 in 2021, while outpatient visits were 356,610, slightly down from 357,611 in 2021[82]. - In 2022, Nantong Ruici Hospital's revenue reached RMB 631.1 million[82]. - The health check business received a total of 3,258,925 customers, generating revenue of RMB 1,765.39 million, which represents a 4.1% increase compared to 2021[84]. - The company continues to implement a dual-brand strategy with "Ruici Health Check" and "Xingyuan International Health Check," focusing on key markets in Shanghai and Jiangsu while exploring new markets in the Greater Bay Area[84]. - The company launched the second phase of the Xinyuanhui International Health Check-up Center in September 2022, aiming to meet diverse medical service needs[106]. Strategic Initiatives - The company aims to reduce greenhouse gas emissions by 20% by 2025, with specific steps outlined to achieve this target[68]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[65]. - The company aims to enhance operational efficiency and meet new consumer demands for health check services in the post-pandemic era[85]. - The management team expresses confidence in the significant development potential of the healthcare industry, driven by a large population base, aging trends, technological innovation, and deepening healthcare reforms[85]. - The company is committed to high-quality development in the healthcare service industry as part of the 14th Five-Year Plan[104]. Governance and Compliance - As of December 31, 2022, the group had no significant legal disputes[11]. - There were no significant transactions or contracts involving directors or their related entities during the year ended December 31, 2022[1]. - The group did not pay any remuneration to directors or the top five highest-paid individuals as bonuses for joining or leaving the group during the year ended December 31, 2022[4]. - The group has adopted a share option scheme as an incentive for directors and eligible employees[4]. - The group confirmed compliance with a non-competition agreement established with its controlling shareholders as of December 31, 2022[8]. - The board of directors consists of seven members, including executive and independent non-executive directors[24]. Environmental and Safety Measures - The total water consumption was reported at 500,000 cubic meters, with a density of 0.5 cubic meters per production unit[67]. - The company has implemented new safety measures, resulting in a 30% reduction in workplace accidents over the past three years[66]. - The total amount of hazardous waste generated was reported at 1,000 tons, with a goal to reduce this by 15% in the next fiscal year[62]. - The company has identified and addressed significant climate-related risks, implementing a comprehensive policy to mitigate these impacts[61]. Financial Position - The total assets as of December 31, 2022, amounted to RMB 4,566.9 million, an increase from RMB 4,536.2 million in 2021[77]. - The total liabilities as of December 31, 2022, were RMB 3,662.0 million, a decrease from RMB 3,948.8 million in 2021[77]. - The company's current liabilities exceeded current assets by RMB 797.5 million as of December 31, 2022, compared to RMB 588.4 million in 2021[155]. - Cash and cash equivalents as of December 31, 2022, were RMB 720.1 million, down from RMB 771.3 million in 2021[156]. - The debt-to-equity ratio improved to 63.6% as of December 31, 2022, compared to 77.1% in 2021, due to a decrease in net financing and an increase in total equity[167]. Board Diversity and Development - The board consists of 4 executive directors (57.1%) and 3 independent non-executive directors (42.9%) as of December 31, 2022[190][191]. - The gender diversity on the board is 4 males (57.1%) and 3 females (42.9%)[193][194]. - The company aims for a minimum gender ratio of 10% for both the board and senior management, with currently 50% of senior management being female[195]. - Approximately 80.7% of the total workforce are female employees[195]. - The company provides ongoing professional development for all directors, ensuring they stay updated on relevant laws and regulations[199].
瑞慈医疗(01526) - 2022 - 年度财报